Roivant Sciences (NASDAQ:ROIV – Get Free Report) will be announcing its earnings results before the market opens on Thursday, August 8th. Analysts expect the company to announce earnings of ($0.21) per share for the quarter. Persons interested in listening to the company’s earnings conference call can do so using this link.
Roivant Sciences (NASDAQ:ROIV – Get Free Report) last announced its earnings results on Thursday, May 30th. The company reported ($0.28) EPS for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.03. The company had revenue of $28.93 million during the quarter, compared to the consensus estimate of $32.46 million. Roivant Sciences had a negative return on equity of 25.05% and a net margin of 3,484.86%. On average, analysts expect Roivant Sciences to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Roivant Sciences Stock Performance
NASDAQ:ROIV opened at $10.33 on Wednesday. The company has a quick ratio of 25.24, a current ratio of 25.24 and a debt-to-equity ratio of 0.07. Roivant Sciences has a twelve month low of $8.24 and a twelve month high of $13.24. The stock has a market cap of $7.63 billion, a P/E ratio of 2.04 and a beta of 1.24. The firm’s fifty day simple moving average is $10.78 and its 200 day simple moving average is $10.86.
Analyst Upgrades and Downgrades
View Our Latest Analysis on Roivant Sciences
About Roivant Sciences
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.
Recommended Stories
- Five stocks we like better than Roivant Sciences
- Why Are These Companies Considered Blue Chips?
- Uber’s Earnings Beat: Rideshare and Delivery Surge
- What is a Low P/E Ratio and What Does it Tell Investors?
- Hims & Hers Reports Stellar Quarter: Stock Set for a Rally
- What Investors Need to Know to Beat the Market
- Cloudflare Stock Flares Up on Solid EPS Beat and Raised Guidance
Receive News & Ratings for Roivant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roivant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.